We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ELVN market cap is 1.11B. The company's latest EPS is USD -1.4651 and P/E is -4.31.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.25M | -22.73M | -25.99M | -24.6M | -27.07M |
| Net Income | -20.77M | -19.37M | -22.74M | -19.95M | -23.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.12M | -41.7M | -51.44M | -34.27M | -83.53M |
| Net Income | -23.46M | -49.22M | -51.38M | 1.49M | -71.58M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 274.04M | 271.87M | 342.78M | 327.04M | 305.43M |
| Total Liabilities | 12.29M | 25.96M | 25.07M | 22.11M | 17.03M |
| Total Equity | 261.75M | 245.91M | 317.71M | 304.93M | 288.4M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 33.3M | 90.84M | 93.65M | 91.96M | 271.87M |
| Total Liabilities | 4.38M | 6.41M | 7.62M | 1.83M | 25.96M |
| Total Equity | 28.92M | 84.44M | 86.03M | 90.13M | 245.91M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -48.79M | -61.27M | -23.36M | -43.8M | -55.99M |
| Investing | -187.1M | -148.41M | -17.89M | -51.55M | -36.72M |
| Financing | 234.2M | 234.29M | 90.27M | 92.08M | 93.19M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.88M | -37.4M | -46.77M | -35.57M | -61.27M |
| Investing | -24.06M | -16.72M | -1.63M | 76.52M | -148.41M |
| Financing | 43.58M | 96.88M | 49.1M | -1.23M | 234.29M |
| Market Cap | 1.11B |
| Price to Earnings Ratio | -4.31 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3.08 |
| Price to Book Ratio | 1.26 |
| Dividend Yield | - |
| Shares Outstanding | 48.86M |
| Average Volume (1 week) | 194.23k |
| Average Volume (1 Month) | 188.62k |
| 52 Week Change | 56.95% |
| 52 Week High | 30.03 |
| 52 Week Low | 10.9001 |
| Spread (Intraday) | 26.1 (72.3%) |
| Company Name | Enliven Therapeutics Inc |
| Address |
corporation trust center 1209 orange st wilmington, delaware 19801 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
